Skip to content

Study · Observational study · n = 355 · 2026

5 results

Optic Ischaemic Neuropathy in Incretin-Based Therapy: A Comparative Analysis of Real-World Safety Data.

Kakkar AK, Payra S, Charaya A

Diabetes, obesity & metabolism8 Jun 2026

PMID42259643 (opens in a new tab)DOI10.1111/dom.70952 (opens in a new tab)PepBankPUB-42259643
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studySafety outcome

    Among semaglutide-associated optic ischaemic neuropathy reports, disability was documented in 18% of cases.

    In plain wordsAmong semaglutide-associated optic ischaemic neuropathy reports, disability was documented in 18% of cases.

    Peptide
    Semaglutide
    Outcome
    Not applicableDisability in semaglutide-associated reports
    Study

    n = 355

    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated

    Measurements

    Disability
    18%
    semaglutide-associated reports

    Source sentences

    Summary
    Among semaglutide-associated reports, mean age was 59 years; disability was documented in 18% and hospitalization in 11% of cases.
    5 context sentences
    Summary · context
    Semaglutide demonstrated a strong post-marketing safety signal for optic ischaemic neuropathy (355 reports; ROR 94.45, 95% CI: 83.02-107.45; PRR 93.77, 95% CI: 82.48-106.61).
    Summary · context
    This study used the FDA Adverse Event Reporting System to evaluate and compare pharmacovigilance signals for optic ischaemic neuropathy across six incretin-based therapies.
    Summary · context
    Adverse event reports from each drug's approval date through Q3 2025 were extracted using OpenVigil 2.1.
    Summary · context
    The Medical Dictionary for Regulatory Activities term "optic ischaemic neuropathy" was used as the outcome.
    Summary · context
    Disproportionality analysis was performed using reporting odds ratio (ROR) and proportional reporting ratio (PRR) with 95% confidence intervals, applying Evans' criteria, restricted to primary suspect drug reports.
  2. 02HumanObservational studySafety outcome

    Among semaglutide-associated optic ischaemic neuropathy reports, hospitalization was documented in 11% of cases.

    In plain wordsAmong semaglutide-associated optic ischaemic neuropathy reports, hospitalization was documented in 11% of cases.

    Peptide
    Semaglutide
    Outcome
    Not applicableHospitalization in semaglutide-associated reports
    Study

    n = 355

    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated

    Measurements

    Hospitalization
    11%
    semaglutide-associated reports

    Source sentences

    Summary
    Among semaglutide-associated reports, mean age was 59 years; disability was documented in 18% and hospitalization in 11% of cases.
    5 context sentences
    Summary · context
    Semaglutide demonstrated a strong post-marketing safety signal for optic ischaemic neuropathy (355 reports; ROR 94.45, 95% CI: 83.02-107.45; PRR 93.77, 95% CI: 82.48-106.61).
    Summary · context
    This study used the FDA Adverse Event Reporting System to evaluate and compare pharmacovigilance signals for optic ischaemic neuropathy across six incretin-based therapies.
    Summary · context
    Adverse event reports from each drug's approval date through Q3 2025 were extracted using OpenVigil 2.1.
    Summary · context
    The Medical Dictionary for Regulatory Activities term "optic ischaemic neuropathy" was used as the outcome.
    Summary · context
    Disproportionality analysis was performed using reporting odds ratio (ROR) and proportional reporting ratio (PRR) with 95% confidence intervals, applying Evans' criteria, restricted to primary suspect drug reports.
  3. 03HumanObservational studySafety outcome

    In primary-suspect pharmacovigilance reports, semaglutide had an optic ischaemic neuropathy reporting signal (355 reports; ROR 94.45, 95% CI 83.02-107.45; PRR 93.77, 95% CI 82.48-106.61).

    In plain wordsIn primary-suspect safety reports, semaglutide had an optic ischaemic neuropathy reporting signal; this does not measure incidence.

    Peptide
    Semaglutide
    Outcome
    IncreaseOptic ischaemic neuropathy safety signal
    Study

    n: not reported in source

    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated

    Measurements

    ROR
    94.45
    95% CI 83.02-107.45
    PRR
    93.77
    95% CI 82.48-106.61

    Source sentences

    Summary
    Semaglutide demonstrated a strong post-marketing safety signal for optic ischaemic neuropathy (355 reports; ROR 94.45, 95% CI: 83.02-107.45; PRR 93.77, 95% CI: 82.48-106.61).
    4 context sentences
    Summary · context
    This study used the FDA Adverse Event Reporting System to evaluate and compare pharmacovigilance signals for optic ischaemic neuropathy across six incretin-based therapies.
    Summary · context
    Adverse event reports from each drug's approval date through Q3 2025 were extracted using OpenVigil 2.1.
    Summary · context
    The Medical Dictionary for Regulatory Activities term "optic ischaemic neuropathy" was used as the outcome.
    Summary · context
    Disproportionality analysis was performed using reporting odds ratio (ROR) and proportional reporting ratio (PRR) with 95% confidence intervals, applying Evans' criteria, restricted to primary suspect drug reports.
  4. 04HumanObservational studySafety outcome

    In primary-suspect pharmacovigilance reports, tirzepatide had an optic ischaemic neuropathy reporting signal (49 reports; ROR 2.94, 95% CI 2.20-3.93; PRR 2.94, 95% CI 2.20-3.93).

    In plain wordsIn primary-suspect safety reports, tirzepatide had an optic ischaemic neuropathy reporting signal; this does not measure incidence.

    Peptide
    Tirzepatide
    Outcome
    IncreaseOptic ischaemic neuropathy safety signal
    Study

    n: not reported in source

    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated

    Measurements

    ROR
    2.94
    95% CI 2.20-3.93
    PRR
    2.94
    95% CI 2.20-3.93

    Source sentences

    Summary
    Tirzepatide and liraglutide also exhibited significant safety signals (49 reports; ROR 2.94, 95% CI: 2.20-3.93; PRR 2.94, 95% CI: 2.20-3.93; and 13 reports; ROR 4.58, 95% CI: 2.65-7.91; PRR 4.58, 95% CI: 2.65-7.91, respectively).
    4 context sentences
    Summary · context
    This study used the FDA Adverse Event Reporting System to evaluate and compare pharmacovigilance signals for optic ischaemic neuropathy across six incretin-based therapies.
    Summary · context
    Adverse event reports from each drug's approval date through Q3 2025 were extracted using OpenVigil 2.1.
    Summary · context
    The Medical Dictionary for Regulatory Activities term "optic ischaemic neuropathy" was used as the outcome.
    Summary · context
    Disproportionality analysis was performed using reporting odds ratio (ROR) and proportional reporting ratio (PRR) with 95% confidence intervals, applying Evans' criteria, restricted to primary suspect drug reports.
  5. 05HumanObservational studySafety outcome

    In primary-suspect pharmacovigilance reports, liraglutide had an optic ischaemic neuropathy reporting signal (13 reports; ROR 4.58, 95% CI 2.65-7.91; PRR 4.58, 95% CI 2.65-7.91).

    In plain wordsIn primary-suspect safety reports, liraglutide had an optic ischaemic neuropathy reporting signal; this does not measure incidence.

    Peptide
    Liraglutide
    Outcome
    IncreaseOptic ischaemic neuropathy safety signal
    Study

    n: not reported in source

    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated

    Measurements

    ROR
    4.58
    95% CI 2.65-7.91
    PRR
    4.58
    95% CI 2.65-7.91

    Source sentences

    Summary
    Tirzepatide and liraglutide also exhibited significant safety signals (49 reports; ROR 2.94, 95% CI: 2.20-3.93; PRR 2.94, 95% CI: 2.20-3.93; and 13 reports; ROR 4.58, 95% CI: 2.65-7.91; PRR 4.58, 95% CI: 2.65-7.91, respectively).
    4 context sentences
    Summary · context
    This study used the FDA Adverse Event Reporting System to evaluate and compare pharmacovigilance signals for optic ischaemic neuropathy across six incretin-based therapies.
    Summary · context
    Adverse event reports from each drug's approval date through Q3 2025 were extracted using OpenVigil 2.1.
    Summary · context
    The Medical Dictionary for Regulatory Activities term "optic ischaemic neuropathy" was used as the outcome.
    Summary · context
    Disproportionality analysis was performed using reporting odds ratio (ROR) and proportional reporting ratio (PRR) with 95% confidence intervals, applying Evans' criteria, restricted to primary suspect drug reports.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 5Current

    27 Oct 2026, 16:36 UTC

    Study data updated · source update from Europe PMC

  2. Version 4

    12 Oct 2026, 11:11 UTC

    Study results updated

  3. Versions 2 to 3

    9 Oct 2026, 03:07 UTC

    The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  4. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.